MEASUREMENT OF SERUM CYTOKINE LEVELS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

被引:0
|
作者
VERHOEF, GEG
DESCHOUWER, P
CEUPPENS, JL
VANDAMME, J
GOOSSENS, W
BOOGAERTS, MA
机构
[1] CATHOLIC UNIV LEUVEN,DEPT HEMATOL,B-3000 LOUVAIN,BELGIUM
[2] CATHOLIC UNIV LEUVEN,DEPT CLIN IMMUNOL,B-3000 LOUVAIN,BELGIUM
[3] CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sera of 25 healthy controls and 75 patients suffering from myelodysplastic syndromes (MDS) were investigated for serum concentration of interleukin-1alpha (IL-1alpha), IL-3, IL-6, granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), erythropoietin (Epo), and tumor necrosis factor-alpha (TNF-alpha). According to French-American-British (FAB) classification, 21 refractory anemia (RA), seven refractory anemia with ring sideroblasts (RARS), 15 chronic myelomonocytic leukemia (CMML), 12 refractory anemia with excess of blasts (RAEB), and 20 RAEB in transformation (RAEBt) were examined. TNF-alpha levels were inversely correlated with lower levels of hemoglobin concentration (r = -0.31, p = 0.005), irrespective of the requirements for transfusion in anemic MDS patients. Significant differences in TNF-alpha levels between CMML (26.2 +/- 5.9 pg/ml) and the FAB subgroups (16.1 +/- 1.6 pg/ml) were detected. There was an overall inverse relationship between the level of erythropoietin and the degree of anemia, but a wide range of Epo response between patients with similar hemoglobin concentrations. Serum levels of IL-1alpha and GM-CSF were undetected in most of the patients. In 57% of the samples there were detectable levels of G-CSF, without a correlation of the serum levels with blood cell counts, nor with any of the FAB subcategories. Overall, 29% and 25% of the patient sera exhibited elevated IL-3 and IL-6 levels, respectively. There was no correlation of the serum levels with any of the blood counts, other cytokines, nor FAB subcategories. In conclusion, simple negative feedback mechanism between a specific cytokine and the production of blood cells seems not to be the case in MDS, except for red cell production and erythropoietin concentration. Our data may suggest the involvement of TNF-alpha in the pathogenesis of anemia in MDS.
引用
收藏
页码:1268 / 1272
页数:5
相关论文
共 50 条
  • [31] Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes
    Stauder, R.
    Germing, U.
    Sperr, W.
    Valent, P.
    Zwierzina, H.
    Ulmer, H.
    Loeffler-Ragg, J.
    LEUKEMIA RESEARCH, 2009, 33 : S71 - S71
  • [32] Serum cytokine levels in uremic patients
    Erturk, S
    Ates, K
    Duman, N
    Tutkak, H
    Ayli, D
    Karatan, O
    Erbay, B
    Ertug, E
    NEPHRON, 1996, 72 (03): : 492 - 492
  • [33] Levels of circulating endothelial adhesion molecules in patients with myelodysplastic syndromes
    Südhoff, T
    Germing, U
    Aul, C
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 20 (01) : 167 - 172
  • [34] Anti-cytokine therapy produces response in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Gezer, S
    Gregory, SA
    Venugopal, P
    Kaizer, H
    Dong, LM
    Span, L
    Hines, C
    Thomas, R
    Alvi, S
    Mundle, SD
    Shetty, V
    Borek, R
    Loew, J
    Reza, S
    Robin, EL
    Rifkin, SD
    Alston, D
    Hernandez, BM
    Shah, R
    Hsu, WT
    Dar, S
    Preisler, HD
    BLOOD, 1996, 88 (10) : 2310 - 2310
  • [35] SERUM DEOXYTHYMIDINE KINASE IN MYELODYSPLASTIC SYNDROMES
    AUL, C
    GATTERMANN, N
    GERMING, U
    WINKELMAN, M
    HEYLL, A
    RUNDE, V
    SCHNEIDER, W
    CANCER, 1994, 73 (02) : 322 - 327
  • [36] Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes
    Yanagisawa, Hiroto
    Kawabata, Hiroshi
    Ueda, Yusuke
    Arita, Kotaro
    Iwao-Kawanami, Haruka
    Sakai, Tomoyuki
    Kawanami, Takafumi
    Yamada, Kazunori
    Mizuta, Shuichi
    Fukushima, Toshihiro
    Masaki, Yasufumi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 81 - 88
  • [37] Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes
    Hiroto Yanagisawa
    Hiroshi Kawabata
    Yusuke Ueda
    Kotaro Arita
    Haruka Iwao-Kawanami
    Tomoyuki Sakai
    Takafumi Kawanami
    Kazunori Yamada
    Shuichi Mizuta
    Toshihiro Fukushima
    Yasufumi Masaki
    International Journal of Hematology, 2022, 116 : 81 - 88
  • [38] Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes
    Wallvik, J
    Stenke, L
    Bernell, P
    Nordahl, G
    Hippe, E
    Hast, R
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (03) : 180 - 186
  • [39] The myelodysplastic syndromes: heterogeneneity on many levels
    Curtin, PT
    BLOOD, 2004, 103 (04) : 1181 - 1182
  • [40] Impact of cytokine gene polymorphisms in myelodysplastic syndromes (MDS)
    Serio, B.
    Risitano, A. M.
    Jankowska, A.
    Nearman, Z.
    O'Keefe, C.
    Rotoli, B.
    Selleri, C.
    Maciejewski, J. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 38 - 38